Skip to main content

Table 2 HIV (+) subject immunologic and HAART related characteristics

From: Increased pericardial fat accumulation is associated with increased intramyocardial lipid content and duration of highly active antiretroviral therapy exposure in patients infected with human immunodeficiency virus: a 3T cardiovascular magnetic resonance feasibility study

Immunologic characteristic

Mean ± SD

Range

Prevalence

HIV History

 Length of HIV diagnosis, months

196 ± 99

48–360

 Previous history of AIDS-defining diagnosis, %

25

---

 Previous history of opportunistic infections, %

19

---

 Undetectable viral load > 3 years, %

100

---

 Compliance with HAART > 3 years, %

99

90–100

HAART-induced side effects

 Metabolic syndrome, %

22

---

 Lipodystrophy, %

78

---

 Lipoatrophy, %

63

---

 Lipoaccumulation, %

67

---

HAART Exposure

 Cumulative HAART (any agent), months

157 ± 88

36–336

 Cumulative exposure PI, months

91 ± 57

0–249

 Cumulative exposure NRTI, months

163 ± 122

40–464

 Cumulative exposure “high risk” PI, months

47 ± 33

0–103

 Cumulative exposure NNRTI, monthsa

22 ± 63

0–156

 Cumulative exposure INSTI, monthsa

5.5 ± 12.6

0–48

 Cumulative exposure “high risk” NRTI, monthsa

44.2 ± 73.9

0–273

Immunologic History

 CD4+ cell counta

594 ± 326

242–2597

 CD8+ cell counta

686 ± 356

312–1944

 CD4+/CD8+ ratioa

78 ± 47

30–313

  1. PI protease inhibitors, NRTI nucleoside reverse transcriptase inhibitors, NNRTI non-nucleoside reverse transcriptase inhibitors, INSTI integrase strand transfer inhibitors, High risk PI’s amprenavir, fosampenavir, indinavir, lopinavir, High risk NRTI’s abacavir, didanosine
  2. aData reported as mean + standard deviation or median with interquartile range